↓ Skip to main content

Dove Medical Press

Article Metrics

What is this page? Embed badge

Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery

Overview of attention for article published in Vascular Health and Risk Management, October 2013
Altmetric Badge

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
55 Mendeley
Summary Twitter Dimensions citations
Title
Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery
Published in
Vascular Health and Risk Management, October 2013
DOI 10.2147/vhrm.s51244
Pubmed ID
24124376
Authors

Yasufumi Kuroda, Chie Hirayama, Hitoshi Hotoda, Yasuhiro Nishikawa, Akinori Nishikawi

Abstract

Edoxaban is an oral, once-daily, selective, direct factor Xa inhibitor approved in Japan for the prevention of venous thromboembolism following major orthopedic surgery. Currently, edoxaban is in Phase III clinical development for the prevention of stroke and systemic embolic events in patients with atrial fibrillation, and for the treatment and prevention of recurrences of venous thromboembolism. This report describes the adverse drug reactions (ADRs) spontaneously reported during early postmarketing phase vigilance from the time of its commercial launch in Japan.

View on publisher site

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 2%
Portugal 1 2%
Slovenia 1 2%
Unknown 52 95%

Demographic breakdown

Readers by professional status Count As %
Student > Master 14 25%
Other 7 13%
Researcher 5 9%
Student > Postgraduate 5 9%
Student > Bachelor 4 7%
Other 13 24%
Unknown 7 13%
Readers by discipline Count As %
Medicine and Dentistry 29 53%
Nursing and Health Professions 4 7%
Pharmacology, Toxicology and Pharmaceutical Science 3 5%
Biochemistry, Genetics and Molecular Biology 2 4%
Engineering 2 4%
Other 6 11%
Unknown 9 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 October 2013.
All research outputs
#15,281,593
of 22,725,280 outputs
Outputs from Vascular Health and Risk Management
#500
of 753 outputs
Outputs of similar age
#127,575
of 207,105 outputs
Outputs of similar age from Vascular Health and Risk Management
#15
of 19 outputs
Altmetric has tracked 22,725,280 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 753 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,105 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.

This page is hosted by Altmetric on behalf of Dove Medical Press.